Brokerages Set AstraZeneca PLC (LON:AZN) Target Price at £153.33

AstraZeneca PLC (LON:AZN) has been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is £153.33.

Several research analysts have commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a £180 price objective on shares of AstraZeneca in a research note on Friday, June 26th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and set a £115 price objective on shares of AstraZeneca in a research note on Friday, June 26th. Finally, Citigroup lifted their price objective on shares of AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a research note on Friday, April 10th.

AstraZeneca Trading Up 0.4%

AZN stock opened at £141.56 on Friday. The firm has a fifty day moving average price of £137.59 and a 200 day moving average price of £141.26. AstraZeneca has a fifty-two week low of £101.03 and a fifty-two week high of £157.32. The company has a debt-to-equity ratio of 71.66, a quick ratio of 0.59 and a current ratio of 0.91. The firm has a market cap of £219.55 billion, a PE ratio of 21.32, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.